The glucagon receptor is required for the adaptive metabolic response to fasting
about
FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation responseAlpha-, Delta- and PP-cells: Are They the Architectural Cornerstones of Islet Structure and Co-ordination?Energy metabolism in the liverPhysiology of proglucagon peptides: role of glucagon and GLP-1 in health and diseaseRole of mitochondria in nonalcoholic fatty liver diseaseCholine supplementation promotes hepatic insulin resistance in phosphatidylethanolamine N-methyltransferase-deficient mice via increased glucagon actionRegulator of G protein signaling (RGS16) inhibits hepatic fatty acid oxidation in a carbohydrate response element-binding protein (ChREBP)-dependent mannerNiclosamide reduces glucagon sensitivity via hepatic PKA inhibition in obese mice: Implications for glucose metabolism improvements in type 2 diabetesMajor facilitator superfamily domain-containing protein 2a (MFSD2A) has roles in body growth, motor function, and lipid metabolismEnergy-sensing factors coactivator peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α) and AMP-activated protein kinase control expression of inflammatory mediators in liver: induction of interleukin 1 receptor antagonistGlucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis?Metabolism Disrupting Chemicals and Metabolic DisordersStructure of the full-length glucagon class B G-protein-coupled receptor.Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes.Thioesterase superfamily member 2 (Them2) and phosphatidylcholine transfer protein (PC-TP) interact to promote fatty acid oxidation and control glucose utilization.High Plasma Glucagon Levels Correlate with Waist-to-Hip Ratio, Suprailiac Skinfold Thickness, and Deep Subcutaneous Abdominal and Intraperitoneal Adipose Tissue Depots in Nonobese Asian Indian Males with Type 2 Diabetes in North IndiaOCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin.Glucagon and lipid interactions in the regulation of hepatic AMPK signaling and expression of PPARalpha and FGF21 transcripts in vivo.Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeoverEffects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humansNovel insight into glucagon receptor action: lessons from knockout and transgenic mouse models.Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes MellitusCrbpI modulates glucose homeostasis and pancreas 9-cis-retinoic acid concentrations.Glucagon stimulates hepatic FGF21 secretion through a PKA- and EPAC-dependent posttranscriptional mechanism.RETRACTED: Hepatic glucagon action is essential for exercise-induced reversal of mouse fatty liver.Lipocalin 13 protein protects against hepatic steatosis by both inhibiting lipogenesis and stimulating fatty acid β-oxidation.Remodeling of hepatic metabolism and hyperaminoacidemia in mice deficient in proglucagon-derived peptides.Exercise intensity modulation of hepatic lipid metabolismGlucagon-to-insulin ratio is pivotal for splanchnic regulation of FGF-21 in humansTreatment of Obese Insulin-Resistant Mice With an Allosteric MAPKAPK2/3 Inhibitor Lowers Blood Glucose and Improves Insulin SensitivityActivation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21Transcriptional and Chromatin Regulation during Fasting - The Genomic EraAngptl4 links α-cell proliferation following glucagon receptor inhibition with adipose tissue triglyceride metabolism.Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease.VASP increases hepatic fatty acid oxidation by activating AMPK in mice.The microRNA-124-iGluR2/3 pathway regulates glucagon release from alpha cells.Oxyntomodulin increases intrinsic heart rate through the glucagon receptor.Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes.5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) effect on glucose production, but not energy metabolism, is independent of hepatic AMPK in vivo.Diet macronutrients composition in nonalcoholic Fatty liver disease: a review on the related documents.
P2860
Q24653481-D98E9A55-9AF3-4D34-92F4-69AB4FAB8282Q26799155-B645A616-2C95-494B-8E01-2C68D3480B55Q26996783-CA58D1AD-F149-44C1-AEC5-D2B86B9D2893Q27027920-709FA892-CFA8-492B-AE44-FE8FD3313058Q27028142-AE495536-8932-4089-9E8D-F5B000B8883EQ28279881-4C71082D-FA24-4475-83ED-D8F25A11F39AQ28306219-15326C84-A074-44F3-8B23-B64360300223Q28359714-75E86392-B982-4CCC-B67B-E6DB1F009E41Q28485382-302933DE-E068-4B97-9EEA-032493F4162AQ28569816-0C3B53B1-C0A5-4917-80A1-D2B66C2C025AQ28571194-A037D3BA-F480-4A40-B5FC-0E8C97630DFAQ29248099-64E64708-D5D8-4F96-A6FA-036DD0437460Q30274644-E892A045-0FDE-47DF-A52A-D6679B16DDA1Q30502199-0D2604C9-EFBD-408E-BD18-7E2678CFB968Q33743689-438D48F9-AB96-4AEA-9D92-241600E3B725Q33786795-812FEB70-A280-4F78-8C68-14BF8A34AD40Q33919545-8CB4E2E1-1632-4A85-B296-B98BCA72758DQ34215218-99D3306C-777F-460D-BA20-AA69328548D1Q34244209-ED762B35-52B8-4F91-985C-8F436DF811E1Q34526962-87B79409-3778-49A3-AD7B-56A2C53477C8Q34871186-91E04B5E-768F-4238-946E-02BEA1D59750Q35062439-59C12656-17A3-4E3E-A238-B1E274D9AACCQ35139983-4DE8D66C-0CA4-45D2-A03D-8DE6B7D20774Q35147964-DC592FCA-1737-42E6-8DE1-4982EA573F7FQ35405051-B745AD71-9E8B-40A1-8B7B-38CC815E32C9Q35515576-BB2F62B5-54FB-4C0C-B8D4-47B4F732BAB2Q35612382-1B6468EE-7D57-4CF1-8A0F-16FF69EC2DB7Q35875980-236E0A51-0CD2-4FBA-B3A5-0AB9954D93DCQ35929501-2F0174FE-EE29-46F1-8D1D-A69197867DFDQ36104668-F06C8C28-C463-4A45-BFF5-FC23C4E02FD2Q36127237-BE845C28-BDC8-42D8-8DA1-CDFEC55F2639Q36355517-819DB637-58C9-4976-9BAC-37C7866642A5Q36394289-E9E8DE64-0061-4E78-AAB1-4340A86C413AQ36788344-A27F1A48-F136-478F-B0A6-7CDC27248FC4Q36867436-EA5AF928-71D0-4563-A2AC-5AABB9B53B2AQ37269420-0B80C8F4-4B5E-4818-BBEF-792596F5837FQ37344159-1006F14B-7A7E-4EE3-B0A9-FDA316ABAEFCQ37360316-9FEB130C-D350-4C8E-AF6D-9A6A172CF416Q37608516-37F4EB34-40BA-4FE1-A4DF-99ED9576EA9BQ37631629-37785E1B-328B-433A-8F07-9638B08C5D15
P2860
The glucagon receptor is required for the adaptive metabolic response to fasting
description
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2008
@ast
im November 2008 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2008/11/01)
@sk
vědecký článek publikovaný v roce 2008
@cs
wetenschappelijk artikel (gepubliceerd op 2008/11/01)
@nl
наукова стаття, опублікована в листопаді 2008
@uk
مقالة علمية (نشرت في نوفمبر 2008)
@ar
name
The glucagon receptor is required for the adaptive metabolic response to fasting
@ast
The glucagon receptor is required for the adaptive metabolic response to fasting
@en
The glucagon receptor is required for the adaptive metabolic response to fasting
@nl
type
label
The glucagon receptor is required for the adaptive metabolic response to fasting
@ast
The glucagon receptor is required for the adaptive metabolic response to fasting
@en
The glucagon receptor is required for the adaptive metabolic response to fasting
@nl
prefLabel
The glucagon receptor is required for the adaptive metabolic response to fasting
@ast
The glucagon receptor is required for the adaptive metabolic response to fasting
@en
The glucagon receptor is required for the adaptive metabolic response to fasting
@nl
P2093
P2860
P3181
P1433
P1476
The glucagon receptor is required for the adaptive metabolic response to fasting
@en
P2093
Adriano Maida
Christine Longuet
Elaine M Sinclair
Laurie L Baggio
Maureen J Charron
P2860
P304
P3181
P356
10.1016/J.CMET.2008.09.008
P577
2008-11-01T00:00:00Z